P1178 Effectiveness and safety of advanced combination therapy in patients with Inflammatory Bowel Diseases: single-centre real-world study

Abstract Background The use of advanced combination therapies (ACT) in the management of inflammatory bowel diseases (IBD) is an emerging area of interest. Targeted at the management of patients with refractory disease to monotherapy and extraintestinal manifestations, there is limited data on real-world outcomes for this patient group. We aimed to review the rates of clinical, biochemical and endoscopic remission in patients on ACT at 6 months. Secondary outcomes included assessing safety, reasons for discontinuation and the choice of combination therapy. Methods We conducted a retrospective observational study on patients with IBD receiving ACT at a single Australian tertiary centre. Data extracted from electronic medical records included: ACT regimen, disease phenotype, indication and adverse events. Of the patients commenced on ACT, 24 had been on it for at least 6 months at the time of analysis. Further data was collected on these patients regarding clinical, biochemical and endoscopic outcomes. Clinical remission was defined as SCCAI score